GSK hit with US FDA knockback for COPD application
GlaxoSmithKline received a rejection for the use of its Nucala product in patients with COPD.
GlaxoSmithKline received a rejection for the use of its Nucala product in patients with COPD.
BIOTECH WEEK BOSTON
MilliporeSigma used Biotech Week Boston to discuss the release of its Eshmuno CP-FT resin and how it can improve downstream efficiency.
Seqirus received approval on its cell-based flu vaccine manufacturing process from the FDA, not long after its FY18 earnings showed profitability.